Health
Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management fie
About this update from Eli Lilly And Company
[{"type":"list","items":[{"val":[{"type":"text","content":"Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2).","length":212,"tagName":"p"}]},{"val":[{"type":"text","content":"The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in subjects with obesity or overweight.","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Efficacy endpoints include changes in abdominal subcutaneous fat volume (measured by MRI) and changes in body weight.","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"The study design incorporates a long-term follow-up period after discontinuation of tirzepatide, focusing on key parameters relevant to long-term weight management.","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":621,"olType":false},{"type":"text","content":"NEW TAIPEI CITY, Dec. 24, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management field.","length":562,"tagName":"p"},{"type":"image","alt":"Caliway Biopharmaceuticals (PRNewsfoto/Caliway Biopharmaceuticals)","displaySize":"","headline":null,"caption":"Caliway Biopharmaceuticals (PRNewsfoto/Caliway Biopharmaceuticals)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":118,"url":"https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HuoXtYQNEnRPCFUMNFsLqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd39","width":400,"height":118},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/6b.wT6mFfEqNsOE8h8Rsnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd3...